 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for FTHL17 |
 Gene summary |
| Basic gene information | Gene symbol | FTHL17 |
| Gene name | ferritin, heavy polypeptide-like 17 | |
| Synonyms | CT38 | |
| Cytomap | UCSC genome browser: Xp21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_031894.2, | |
| Description | cancer/testis antigen 38ferritin heavy polypeptide-like 17 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 300308 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000132446 | ||
| HPRD : 02254 | ||
| Vega : OTTHUMG00000021332 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_FTHL17 | |
| BioGPS: 53940 | ||
| Pathway | NCI Pathway Interaction Database: FTHL17 | |
| KEGG: FTHL17 | ||
| REACTOME: FTHL17 | ||
| Pathway Commons: FTHL17 | ||
| Context | iHOP: FTHL17 | |
| ligand binding site mutation search in PubMed: FTHL17 | ||
| UCL Cancer Institute: FTHL17 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | HPA,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of FTHL17 | ||
| Description by TissGene annotations | TissgsKTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for FTHL17 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for FTHL17 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for FTHL17 |
| TissGeneSNV for FTHL17 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.D85N | SKCM | 2 |
| p.D62N | SKCM | 2 |
| p.R54H | CESC | 1 |
| p.I21M | ACC | 1 |
| p.D18E | LUAD | 1 |
| p.A164S | UCEC | 1 |
| p.H80Q | LUAD | 1 |
| p.F53L | BLCA | 1 |
| p.V47A | LUAD | 1 |
| p.M38L | LUAD | 1 |
| p.E108D | UCEC | 1 |
| p.Y30F | LUAD | 1 |
| p.Q113* | SKCM | 1 |
| p.D61E | LUSC | 1 |
| p.Q120L | LUSC | 1 |
| p.R157H | CESC | 1 |
| p.S114G | STAD | 1 |
| p.P89T | LUAD | 1 |
| p.R87M | LUSC | 1 |
| p.R179P | LUSC | 1 |
| p.H80N | THYM | 1 |
| p.D172Y | COAD | 1 |
| p.A104S | BRCA | 1 |
| p.Y35H | PAAD | 1 |
| p.E148D | LUAD | 1 |
| p.K181N | UCEC | 1 |
| p.H66Q | DLBC | 1 |
| p.D85Y | BLCA | 1 |
| p.Q113X | SKCM | 1 |
| p.Q113H | BLCA | 1 |
| p.M71I | BLCA | 1 |
| p.D61Y | LUAD | 1 |
| p.L83I | UCEC | 1 |
| p.L170M | UCEC | 1 |
| p.V153M | PAAD | 1 |
| p.M1T | LUSC | 1 |
| p.D46N | SKCM | 1 |
| p.D127N | UCEC | 1 |
| p.E182* | UCEC | 1 |
| p.R44W | UCEC | 1 |
| p.R157H | UCEC | 1 |
| Top |
| TissGeneCNV for FTHL17 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for FTHL17 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for FTHL17 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for FTHL17 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for FTHL17 |
| TissGeneDrug for FTHL17 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for FTHL17 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0432475 | XX males | 1 | BeFree |
| umls:C1302401 | Adenoma of large intestine | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |